## VITROLIFE GROUP<sup>™</sup>

## Vitrolife AB (publ) announces changes in the Board of Directors

According to plan and as previously announced, Henrik Blomquist will step down as Chairman of the Board of Vitrolife AB (publ) and the Board of Directors has appointed Jón Sigurdsson as the Chairman of the Board with effect from today when Bronwyn Brophy assumes the position as CEO.

The board member Vesa Koskinen, appointed by EQT VIII has at his own request chosen to resign from the Board of Directors of Vitrolife AB (publ). Vesa Koskinen has been a board member since 1 December 2021 and will step down as of today.

"On behalf of the board, I would like to thank Vesa Koskinen for his contributions during his time as a board member", says Jón Sigurdsson, Chairman of the Board of Vitrolife AB (publ).

After the announced changes, the Board consists of the Chairman of the Board Jón Sigurdsson and the board members Henrik Blomquist, Karen Lykke Sørensen, Lars Holmqvist and Pia Marions. Henrik Blomquist will replace Vesa Koskinen in the Audit Committee.

Gothenburg, 1 August 2023 VITROLIFE AB (publ) The Board of Directors

## Contact:

Patrik Tolf, CFO, phone: +46 31 766 90 21

Vitrolife Group is a global provider of medical devices and genetic services. Based on science and advanced research capabilities, we develop services and products for personalized genetic information and medical device products. We are supporting our customers by improving their clinical practice and the outcome of the patient's fertility treatment. Currently, we are approximately 1,100 people worldwide, headquartered in Gothenburg, Sweden.

Vitrolife Group's products and services are available in more than 125 countries, through our own presence in more than 25 countries and a network of distributors. We are a sustainable market leader and aim to be the preferred partner to the IVFclinics by providing superior products and services with the vision to fulfil the dream of having a healthy baby. Vitrolife AB (publ) is listed on Nasdaq Stockholm.

Vitrolife AB (publ), Box 9080, SE-400 92 Gothenburg, Sweden. Corporate identity number 556354-3452.Tel: +46 31 721 80 00. Fax: +46 31 721 80 99. E-mail: info@vitrolife.com. Website: www.vitrolifegroup.com.

This is a translation of the Swedish version of the press release. When in doubt, the Swedish wording prevails.